Sexual & reproductive GnRH agonist
Leuprolide
Regulatory status
Status at a glance
503A compounding status
Not nominated
We found no pending nomination for the 503A bulks list. Unless the substance has another legal pathway (for example, a USP monograph or use in an FDA-approved drug), 503A pharmacies generally may not compound with it.
- FDA approval
- An FDA-approved product contains this peptide
- 503B outsourcing
- Not determined
- Anti-doping (WADA)
- Not on the WADA Prohibited List
- DEA schedule
- Not a controlled substance
About peptide status
Most peptides discussed here are not FDA-approved for any use, and products labeled “research use only” are not for human use. Removal from Category 2 does not authorize compounding. PCAC votes are non-binding recommendations; FDA and HHS make the final decisions.
This is not medical or legal advice, and we do not publish dosing, sourcing or reconstitution information. Talk with a licensed clinician before using any peptide.
If you think you are having a medical emergency, call 911.
Key takeaway
Leuprolide (leuprolide acetate; brands include Lupron, Eligard, and Fensolvi) is a synthetic nonapeptide agonist of gonadotropin-releasing hormone that, given continuously, suppresses the pituitary and shuts down testosterone and estrogen production. It is prescribed for prostate cancer, endometriosis, and precocious puberty, lowering testosterone to castrate levels within two to four weeks. It has been FDA-approved in the U.S. since 1985 and comes in depot formulations lasting from one to six months.
At a glance
- What it is
- A GnRH (LHRH) receptor agonist peptide that suppresses sex-hormone production
- Approved for
- Advanced prostate cancer, endometriosis, uterine fibroids with anemia, and central precocious puberty
- Key fact
- A 3-month depot kept stimulated luteinizing hormone suppressed in most children treated for precocious puberty
- Route
- Subcutaneous or intramuscular depot injection
- Evidence strength
- FDA approved
Summary
Leuprolide is a GnRH agonist FDA-approved since 1985. It suppresses testosterone and estrogen for prostate cancer, endometriosis, and precocious puberty.
What is leuprolide?
Leuprolide, known generically as leuprolide acetate (INN leuprorelin) and sold as Lupron, Lupron Depot, Eligard, Fensolvi, and Camcevi, is a synthetic nine-amino-acid analog of gonadotropin-releasing hormone. The natural hormone is released in pulses by the hypothalamus and tells the pituitary to make luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn drive the testes and ovaries to produce testosterone and estrogen. Leuprolide is a far more potent and longer-lasting version of that signal, first developed under the code TAP-144 and approved in the United States in 1985.
The history of leuprolide
Leuprolide grew directly out of the discovery of GnRH itself. Andrew Schally and Roger Guillemin shared the 1977 Nobel Prize in Physiology or Medicine for isolating and sequencing the hypothalamic releasing hormones, including GnRH. Once the ten-amino-acid structure was known, chemists built analogs that resisted breakdown and bound the receptor more tightly. Leuprolide, with a single amino-acid substitution and an ethylamide tail, was among the first of these "superagonists" to reach the clinic, and its approval in 1985 helped establish medical castration as an alternative to surgical removal of the testes for prostate cancer.
How does leuprolide work?
Leuprolide binds the GnRH receptor on the pituitary, and its effect depends on how it is delivered. A first dose actually stimulates the pituitary, producing a short-lived surge in LH, FSH, and testosterone known as the "flare." Because leuprolide then occupies the receptor continuously rather than in natural pulses, the pituitary gonadotrophs downregulate and desensitize. Within about two to four weeks LH and FSH fall, and testosterone in men, or estrogen in women, drops to castrate or postmenopausal levels.
That sustained suppression is the therapeutic goal, and the table below shows what it does in each condition.
| Condition | What hormone suppression does |
|---|---|
| Prostate cancer | Removing testosterone starves hormone-sensitive tumor cells |
| Endometriosis and fibroids | Lowering estrogen shrinks hormone-driven tissue |
| Central precocious puberty | Switching off the premature hormone signal halts early sexual development and helps preserve adult height |
The flare is why men with advanced prostate cancer are often given an anti-androgen in the first weeks, to blunt any transient worsening. Depot formulations release the drug slowly so a single injection maintains suppression for one, three, four, or six months. In the pediatric registration program, a three-month depot kept stimulated LH suppressed in 78 to 95% of treated children.
Is it FDA-approved?
Editor’s note
Status: Yes. Leuprolide was first approved by the FDA in 1985 as a daily subcutaneous injection, with the long-acting Lupron Depot following in 1989. Over the following decades the FDA cleared additional depot strengths, new indications, and several brands, including Eligard, the Fensolvi pediatric depot, and the ready-to-use Camcevi.
Category: FDA-approved · Primary body area: Sexual & reproductive
Yes. Leuprolide was first approved by the FDA in 1985 as a daily subcutaneous injection, with the long-acting Lupron Depot following in 1989. Over the following decades the FDA cleared additional depot strengths, new indications, and several brands, including Eligard, the Fensolvi pediatric depot, and the ready-to-use Camcevi.
What is leuprolide prescribed for?
Leuprolide is prescribed for:
- Advanced or metastatic prostate cancer, as palliative hormone therapy
- Endometriosis
- Uterine fibroids with associated anemia, usually before surgery and combined with iron
- Central precocious puberty in children
Because it works by suppressing sex hormones, it is contraindicated in pregnancy; the gynecologic and pediatric uses are often time-limited in part to protect bone density.
What are the side effects?
According to the prescribing information, common side effects reflect low sex-hormone levels and the injection itself:
- Hot flashes and sweating
- Injection-site pain or reactions
- Decreased libido and erectile dysfunction
- Fatigue and mood changes
- Bone-density loss with long-term use
More serious considerations include:
- Transient tumor "flare" symptoms in the first weeks of prostate-cancer treatment
- Increased risk of hyperglycemia, diabetes, and cardiovascular events with long-term androgen deprivation
- Rare seizures
- Severe skin reactions
- In children treated for precocious puberty, mood and behavior changes and raised pressure around the brain (pseudotumor cerebri), per the pediatric label
Sources: FDA prescribing information for Lupron Depot, Eligard, and Fensolvi; a trial of the three-month pediatric depot (Lee et al., Journal of Clinical Endocrinology and Metabolism, 2012, DOI: 10.1210/jc.2011-2704), indexed on PubMed; and background on the Nobel-recognized discovery of GnRH. This document is educational and does not constitute medical advice.
Registered human trials
0 registered human trials on ClinicalTrials.gov that we reviewed
Sources
- [1]
- [2]
approved (PDF)
- [3]
pediatric label (PDF)
Compare every peptide’s status in the peptide regulatory status database
More for Sexual & reproductive
View all sexual & reproductive peptides →- FDA-approved Sexual & reproductive
Cetrorelix
Cetrorelix is a synthetic ten-amino acid peptide that blocks the GnRH receptor in the pituitary gland, shutting down the hormone signals that would otherwise trigger early ovulation. It is FDA-approved as Cetrotide, a subcutaneous injection used during IVF to stop a premature LH surge so that eggs can mature and be collected on schedule. It remains a standard part of modern IVF stimulation, valued for acting quickly and for lowering the risk of ovarian hyperstimulation compared with older protocols.
- Not FDA-approved Sexual & reproductive
Compounded-Gonadorelin
It Is and What
Gonadorelin is a synthetic form of the natural reproductive hormone GnRH, used in wellness and men's-health settings as an add-on to testosterone therapy to help preserve fertility and testicular size. The strongest human data come from a different setting. In a 2021 meta-analysis of 420 men with congenital hypogonadotropic hypogonadism across seven studies, pulsatile GnRH began sperm production 5.3 months earlier than gonadotropin therapy (p = 0.004), with no significant difference in sperm concentration (p = 0.37) or pregnancy rate (p = 0.11). Direct evidence for the testosterone add-on use is limited, and there is no FDA-approved gonadorelin product for it.
- FDA-approved Sexual & reproductive
Degarelix
Degarelix (sold as Firmagon) is a synthetic decapeptide that blocks the gonadotropin-releasing hormone receptor, dropping testosterone to castrate levels within a few days and without the initial surge seen with older hormone drugs. It is used to treat advanced prostate cancer and lowers testosterone to castrate levels faster than the agonist leuprolide. It has been FDA-approved in the U.S. since 2008 and is given as a monthly subcutaneous injection.
- FDA-approved Sexual & reproductive
Ganirelix
Ganirelix (originally approved as Antagon) is a synthetic decapeptide that blocks the gonadotropin-releasing hormone receptor, used during fertility treatment to stop an egg from being released too early. Given once daily during ovarian stimulation, it prevents the premature luteinizing hormone surge that could otherwise disrupt an IVF cycle. It has been FDA-approved in the U.S. since 1999 and is given as a small daily subcutaneous injection.
- FDA-approved Sexual & reproductive
Goserelin
Goserelin (goserelin acetate, sold as Zoladex) is a synthetic decapeptide agonist of gonadotropin-releasing hormone delivered as a small implant that suppresses the body's production of testosterone and estrogen. It is used across prostate cancer, breast cancer, and endometriosis, and in one long-term breast-cancer trial it matched standard chemotherapy for survival in certain premenopausal women. It has been FDA-approved in the U.S. since 1989 and is given as a monthly or three-month depot implant.
- FDA-approved Sexual & reproductive
Histrelin
Histrelin (histrelin acetate, sold as Supprelin LA and formerly as Vantas) is a synthetic nonapeptide agonist of gonadotropin-releasing hormone delivered as a small implant that releases drug for about a year. It suppresses the pituitary and the sex hormones it controls, and is used for central precocious puberty in children; a second implant for advanced prostate cancer in adults was discontinued in 2021. The implant products have been FDA-approved in the U.S. since the mid-2000s, and one implant lasts roughly 12 months.